Tags

Type your tag names separated by a space and hit enter

Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
J Control Release. 2021 09 10; 337:258-284.JC

Abstract

The coronavirus disease-19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has taken the world by surprise. To date, a worldwide approved treatment remains lacking and hence in the context of rapid viral spread and the growing need for rapid action, drug repurposing has emerged as one of the frontline strategies in the battle against SARS-CoV2. Repurposed drugs currently being evaluated against COVID-19 either tackle the replication and spread of SARS-CoV2 or they aim at controlling hyper-inflammation and the rampaged immune response in severe disease. In both cases, the target for such drugs resides in the lungs, at least during the period where treatment could still provide substantial clinical benefit to the patient. Yet, most of these drugs are administered systemically, questioning the percentage of administered drug that actually reaches the lung and as a consequence, the distribution of the remainder of the dose to off target sites. Inhalation therapy should allow higher concentrations of the drug in the lungs and lower concentrations systemically, hence providing a stronger, more localized action, with reduced adverse effects. Therefore, the nano-reformulation of the repurposed drugs for inhalation is a promising approach for targeted drug delivery to lungs. In this review, we critically analyze, what nanomedicine could and ought to do in the battle against SARS-CoV2. We start by a brief description of SARS-CoV2 structure and pathogenicity and move on to discuss the current limitations of repurposed antiviral and immune-modulating drugs that are being clinically investigated against COVID-19. This account focuses on how nanomedicine could address limitations of current therapeutics, enhancing the efficacy, specificity and safety of such drugs. With the appearance of new variants of SARS-CoV2 and the potential implication on the efficacy of vaccines and diagnostics, the presence of an effective therapeutic solution is inevitable and could be potentially achieved via nano-reformulation. The presence of an inhaled nano-platform capable of delivering antiviral or immunomodulatory drugs should be available as part of the repertoire in the fight against current and future outbreaks.

Authors+Show Affiliations

Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), 11835 Cairo, Egypt. Electronic address: Salma.nabil@guc.edu.eg.Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), 11835 Cairo, Egypt.Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), 11835 Cairo, Egypt.Institute of Biochemistry, Department of Chemistry, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.Institute of Inorganic Chemistry, Department of Chemistry, , University of Cologne, Greinstraβe 6, 50939 Cologne, Germany.Institute of Inorganic Chemistry, Department of Chemistry, , University of Cologne, Greinstraβe 6, 50939 Cologne, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34293319

Citation

Tammam, Salma N., et al. "Repurpose but Also (nano)-reformulate! the Potential Role of Nanomedicine in the Battle Against SARS-CoV2." Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 337, 2021, pp. 258-284.
Tammam SN, El Safy S, Ramadan S, et al. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. J Control Release. 2021;337:258-284.
Tammam, S. N., El Safy, S., Ramadan, S., Arjune, S., Krakor, E., & Mathur, S. (2021). Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. Journal of Controlled Release : Official Journal of the Controlled Release Society, 337, 258-284. https://doi.org/10.1016/j.jconrel.2021.07.028
Tammam SN, et al. Repurpose but Also (nano)-reformulate! the Potential Role of Nanomedicine in the Battle Against SARS-CoV2. J Control Release. 2021 09 10;337:258-284. PubMed PMID: 34293319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. AU - Tammam,Salma N, AU - El Safy,Sara, AU - Ramadan,Shahenda, AU - Arjune,Sita, AU - Krakor,Eva, AU - Mathur,Sanjay, Y1 - 2021/07/20/ PY - 2021/04/03/received PY - 2021/07/15/revised PY - 2021/07/15/accepted PY - 2021/7/23/pubmed PY - 2021/9/16/medline PY - 2021/7/22/entrez KW - COVID-19 KW - Drug Delivery KW - Drug Repurposing KW - Drug Targeting KW - Inhalation Therapy KW - Nanomedicine SP - 258 EP - 284 JF - Journal of controlled release : official journal of the Controlled Release Society JO - J Control Release VL - 337 N2 - The coronavirus disease-19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has taken the world by surprise. To date, a worldwide approved treatment remains lacking and hence in the context of rapid viral spread and the growing need for rapid action, drug repurposing has emerged as one of the frontline strategies in the battle against SARS-CoV2. Repurposed drugs currently being evaluated against COVID-19 either tackle the replication and spread of SARS-CoV2 or they aim at controlling hyper-inflammation and the rampaged immune response in severe disease. In both cases, the target for such drugs resides in the lungs, at least during the period where treatment could still provide substantial clinical benefit to the patient. Yet, most of these drugs are administered systemically, questioning the percentage of administered drug that actually reaches the lung and as a consequence, the distribution of the remainder of the dose to off target sites. Inhalation therapy should allow higher concentrations of the drug in the lungs and lower concentrations systemically, hence providing a stronger, more localized action, with reduced adverse effects. Therefore, the nano-reformulation of the repurposed drugs for inhalation is a promising approach for targeted drug delivery to lungs. In this review, we critically analyze, what nanomedicine could and ought to do in the battle against SARS-CoV2. We start by a brief description of SARS-CoV2 structure and pathogenicity and move on to discuss the current limitations of repurposed antiviral and immune-modulating drugs that are being clinically investigated against COVID-19. This account focuses on how nanomedicine could address limitations of current therapeutics, enhancing the efficacy, specificity and safety of such drugs. With the appearance of new variants of SARS-CoV2 and the potential implication on the efficacy of vaccines and diagnostics, the presence of an effective therapeutic solution is inevitable and could be potentially achieved via nano-reformulation. The presence of an inhaled nano-platform capable of delivering antiviral or immunomodulatory drugs should be available as part of the repertoire in the fight against current and future outbreaks. SN - 1873-4995 UR - https://www.unboundmedicine.com/medline/citation/34293319/Repurpose_but_also_(nano)-reformulate!_The_potential_role_of_nanomedicine_in_the_battle_against_SARS-CoV2. L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-3659(21)00371-0 DB - PRIME DP - Unbound Medicine ER -